[1] Ferlay J, Soerjomataram I, Dikshit R, et al.Cancer incidence and mortality worldwide: sources, method and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015,136(5): E359-386.
[2] Chen W, Zheng R, Baade PD, et al.Cancer statistics in China,2015[J]. CA Cancer J Clin, 2016,66(2):115-132.
[3] Chang GJ, Rodriguez-Bigas MA, Skibber JM, et al.Lymph node evaluation and survival after curative resection of colon cancer: systematic review[J]. J Natl Cancer Inst, 2007,99(6):433-441.
[4] Leung DW, Cachianes G, Kuang WJ, et al.Vascular endothelial growth factor is a secreted angiogenic mitogen[J]. Science, 1989,246(4935):1306-1309.
[5] Royston D, Jackson DG.Mechanisms of lymphatic metastasis in human colorectal adenocarcinoma[J]. J Pathol, 2009,217(5):608-619.
[6] Saad RS, Kordunsky L, Liu YL, et al.Lymphatic microvessel density as prognostic marker in colorectal cancer[J]. Mod Pathol, 2006, 19(10):1317-1323.
[7] Nagahashi M, Ramachandran S, Rashid OM, et al.Lymphangiogenesis: a new player in cancer progression[J]. World J Gastroenterol, 2010,16(32):4003-4012.
[8] Tacconi C, Correale C, Gandelli A, et al.Vascular Endothelial Growth Factor C Disrupts the Endothelial Lymphatic Barrier to Promote Colorectal Cancer Invasion[J]. Gastroenterology, 2015,148(7):1438-1451.
[9] Zhong D, Li Y, Peng Q, et al.Expression of Tiam1 and VEGF-C correlates with lymphangiogenesis in human colorectal carcinoma[J]. Cancer Biol Ther, 2009,8(8): 689-695.
[10] Song J, Chen W, Cui X, et al.CCBE1 promotes tumor lymphangiogenesis and is negatively regulated by TGFβ signaling in colorectal cancer[J]. Theranostics, 2020,10(5): 2327-2341.
[11] Yin Q, Wang PP, Peng R, et al.MiR-19a enhances cell proliferation, migration, and invasiveness through enhancing lymphangiogenesis by targeting thrombospondin-1 in colorectal cancer[J]. Biochem Cell Biol, 2019,97(6):731-739.
[12] Liu AH, Liu LH, Lu H.Lnc RNA XIST facilitates proliferation and epithelial-mesenchymal transition of colorectal cancer cells through targeting miR‐486‐5p and promoting neuropilin‐2[J]. J Cell Physiol, 2018,234(8):13747-13761.
[13] Favier B, Alam A, Barron P, et al.Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration[J]. Blood, 2006,108(4):1243-1250.
[14] Ou JJ, Wei X, Peng Y, et al.Neuropilin-2 mediates lymphangiogenesis of colorectal carcinoma via a VEGFC/VEGFR3 independent signaling[J]. Cancer Lett, 2015,358(2):200-209.
[15] Ou JJ, Li J, Pan F, et al.Endostatin suppresses colorectal tumor-induced lymphangiogenesis by inhibiting expression of fibronectin extra domain A and integrin α9[J]. J Cell Biochem, 2011,112(8):2106-2114.
[16] Ou JJ, Deng J, Wei X, et al.Fibronectin extra domain A (EDA) sustains CD133(+)/CD44(+) subpopulation of colorectal cancer cells[J]. Stem Cell Res, 2013,11(2):820-833.
[17] Xiang LS, Xie GF, Ou JJ, et al.The Extra Domain A of fibronectin increases VEGF-C expression in colorectal carcinoma involving the PI3K/AKT signaling pathway[J]. PLoS ONE, 2012,7(4):e35378.
[18] Du B, Yang ZY, Zhong XY, et al.Metastasis-associated protein 1 induces VEGF-C and facilitates lymphangiogenesis in colorectal cancer[J]. World J Gastroenterol, 2011,17(9): 1219-1226.
[19] Li ZJ, Ying XJ, Chen HL, et al.Insulin-like growth factor-1 induces lymphangiogenesis and facilitates lymphatic metastasis in colorectal cancer[J]. World J Gastroenterol, 2013,19(43): 7788-7794.
[20] Stacker SA, Williams SP, Karnezis T, et al.Lymphangiogenesis and lymphatic vessel remodelling in cancer[J]. Nat Rev Cancer, 2014,14(3):159-172.
[21] Li X, Liu B, Xiao J, et al.Roles of VEGF-C and Smad4 in the lymphangiogenesis, lymphatic metastasis, and prognosis in colon cancer[J]. J Gastrointest Surg, 2011,15(11):2001-2010.
[22] Sun B, Zhou YM, Fang YT, et al.Colorectal cancer exosomes induce lymphatic network remodeling in lymph nodes[J]. Int J Cancer, 2019,145(6):1648-1659.
[23] Vellinga TT, Kranenburg O, Frenkel N, et al.Lymphangiogenic gene expression is associated with 24 lymph node recurrence and poor prognosis after partial hepatectomy for colorectal liver metastasis[J]. Ann Surg, 2017,266(5):765-771.
[24] Schutz FA, Choueiri TK, Sternberg CN.Pazopanib: clinical development of a potent anti-angiogenic drug[J]. Crit Rev Oncol Hematol, 2011,77(3):163-171.
[25] Zhu GW, Zhao M, Han QH, et al.Pazopanib inhibits tumor growth, lymph-node metastasis and lymphangiogenesis of an orthotopic mouse of colorectal cancer[J]. Cancer Genom Proteom, 2020,17(2):131-139.
[26] Lui ZC, Ma Q, Wang XH, et al.Inhibiting tumor growth of colorectal cancer by blocking the expression of vascular endothelial growth factor receptor 3 using interference vector-based RNA interference[J]. Int J Mol Med, 2010,25(1): 59-64.
[27] Li H, Lai ZJ, Yang H, et al.Hedyotis diffusa Willd. inhibits VEGF-C-mediated lymphangiogenesis in colorectal cancer via multiple signaling pathways[J]. Oncol Rep, 2019,42(3): 1225-1236.
[28] Lin JM, Feng JY, Jin YY, et al.Pien Tze Huang suppresses VEGF-C-mediated lymphangiogenesis in colorectal cancer[J]. Oncol Rep, 2016,36(6):3568-3576.
[29] Liu ZY, Qiu HO, Yuan XJ, et al.Suppression of lymphangiogenesis in human lymphatic endothelial cells by simultaneously blocking VEGF-C and VEGF-D/VEGFR-3 with norcantharidin[J]. Int J Oncol, 2012,41(5):1762-1772.
[30] Saif MW, Knost JA, Chiorean EG, et al.Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer[J]. Cancer Chemoth Pharm, 2016,78(4):815-824.
[31] Li J, Qin SK, Xu RH, et al.Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2015,16(6):619-629.
[32] Sundlisaeter E, Røsland GV, Hertel JK, et al.Increased lymphatic vascular density is seen before colorectal cancers reach stage Ⅱ and growth factor FGF-2 is downregulated in tumor tissue compared with normal mucosa[J]. APMIS, 2009,117(3):212-221.
